# Combination Immunotherapy Targeting Melanoma

> **NCT06739226** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Antigen-specific CAR T, CTL and DCvac to treat melanoma.

## Key facts

- **NCT ID:** NCT06739226
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739226, "Combination Immunotherapy Targeting Melanoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06739226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*